Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepatic Artery Infusion of Carfilzomib for Liver Metastases
NCT07715903Phase 1Not yet recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of carfilzomib in colorectal cancer (CRC), intrahepatic cholangiocarcinoma (ICC) and adrenocortical carcinoma (ACC), sponsored by National Cancer Institute. Primary endpoint: Safety and Dose-Limiting Toxicities (DLTs). Planned start Nov 2026; status: not yet recruiting.
02
Drugs
carfilzomib
03
Conditions
colorectal cancer (CRC)intrahepatic cholangiocarcinoma (ICC)adrenocortical carcinoma (ACC)
Beyond the preview
Go deeper on NCT07715903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07715903.